CoV-2 nucleocapsid antibodies to detect exposure to SARS-CoV-2: results from a prospective cohort study on COVID-19 ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 ...

When the COVID-19 pandemic first began, we saw how quickly the SARS-CoV-2 virus evolved. New variants emerged with mutations ...

University of Arizona has identified non-structural protein 3 (nsp3; PL-pro) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Although several vaccines and drugs are available against SARS-CoV-2, the search for effective therapeutic agents for COVID-19 and future zoonotic coronaviruses continues. The RNA-dependent RNA ...

A Stanford-led team has found two antibodies that can work together to defeat all SARS-CoV-2 variants. More research is needed, but the approach could help in the development of treatments to keep ...

Scientists found that it can bind to human ACE2 receptors, similar to SARS-CoV-2 (the virus behind COVID-19). This suggests it has the potential for animal-to-human transmission. Experts note that ...

Several studies have suggested that COVID-19 may increase a person’s risk of developing cancer or promote metastasis of existing cancer.

(Reuters) - A newly discovered bat coronavirus uses the same cell-surface protein to gain entry into human cells as the SARS-CoV-2 virus that causes COVID-19, raising the possibility that it could ...

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...